Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 1
1995 2
1998 1
1999 1
2001 2
2003 3
2004 3
2005 7
2006 6
2007 5
2008 9
2009 6
2010 4
2011 10
2012 11
2013 14
2014 13
2015 17
2016 13
2017 12
2018 10
2019 9
2020 8
2021 9
2022 15
2023 12
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean i forget[Author] (1,541 results)?
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.
Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, Do Cao C, Kelly A, Barge ML, Lacroix L, Dygai I, Vera P, Rusu D, Schneegans O, Benisvy D, Klein M, Roux J, Eberle MC, Bastie D, Nascimento C, Giraudet AL, Le Moullec N, Bardet S, Drui D, Roudaut N, Godbert Y, Morel O, Drutel A, Lamartina L, Schvartz C, Velayoudom FL, Schlumberger MJ, Leenhardt L, Borget I. Leboulleux S, et al. Among authors: borget i. N Engl J Med. 2022 Mar 10;386(10):923-932. doi: 10.1056/NEJMoa2111953. N Engl J Med. 2022. PMID: 35263518 Clinical Trial.
Données et preuves en vie réelle dans l’évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ?
de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, Borget I, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M. de Pouvourville G, et al. Among authors: borget i. Therapie. 2023 Jan-Feb;78(1):66-80. doi: 10.1016/j.therap.2022.10.067. Epub 2022 Oct 29. Therapie. 2023. PMID: 36446648 French. No abstract available.
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, Benisvy D, Taïeb D, Bardet S, Terroir-Cassou-Mounat M, Anizan N, Bouvier-Morel E, Lamartina L, Lion G, Betrian S, Sajous C, Schiazza A, Garcia ME, Ciappuccini R, Schlumberger M, Al Ghuzlan A, Godbert Y, Borget I. Leboulleux S, et al. Among authors: borget i. Clin Cancer Res. 2023 Jul 5;29(13):2401-2409. doi: 10.1158/1078-0432.CCR-23-0046. Clin Cancer Res. 2023. PMID: 37074727 Free article. Clinical Trial.
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer.
Leboulleux S, Benisvy D, Taieb D, Attard M, Bournaud C, Terroir-Cassou-Mounat M, Lacroix L, Anizan N, Schiazza A, Garcia ME, Ghuzlan AA, Lamartina L, Schlumberger M, Godbert Y, Borget I. Leboulleux S, et al. Among authors: borget i. Thyroid. 2023 Sep;33(9):1124-1129. doi: 10.1089/thy.2023.0240. Epub 2023 Jul 26. Thyroid. 2023. PMID: 37350119 Clinical Trial. No abstract available.
Attentes méthodologiques pour la démonstration de l’efficacité des produits de santé par les études observationnelles.
Cucherat M, Demarcq O, Chassany O, Le Jeunne C, Borget I, Collignon C, Diebolt V, Feuilly M, Fiquet B, Leyrat C, Naudet F, Porcher R, Schmidely N, Simon T, Roustit M. Cucherat M, et al. Among authors: borget i. Therapie. 2024 Oct 22:S0040-5957(24)00168-9. doi: 10.1016/j.therap.2024.10.052. Online ahead of print. Therapie. 2024. PMID: 39537531 Free article. French. No abstract available.
Global thyroid estimates in 2020.
Lamartina L, Leboulleux S, Borget I, Schlumberger M. Lamartina L, et al. Among authors: borget i. Lancet Diabetes Endocrinol. 2022 Apr;10(4):235-236. doi: 10.1016/S2213-8587(22)00048-1. Epub 2022 Mar 7. Lancet Diabetes Endocrinol. 2022. PMID: 35271820 No abstract available.
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.
Jannin A, Giudici F, de la Fouchardière C, Al Ghuzlan A, Wassermann J, Chougnet CN, Drui D, Godbert Y, Ilouz F, Bardet S, Zanetta S, Roudaut N, Batisse Lignier M, Groussin L, Klein M, Zerdoud S, Lamartina L, Baudin E, Decaussin-Petrucci M, Leteurtre E, Borson Chazot F, Do Cao C, Borget I, Hadoux J; ENDOCAN-TUTHYREF Network. Jannin A, et al. Among authors: borget i. Thyroid. 2023 Oct;33(10):1190-1200. doi: 10.1089/thy.2023.0164. Thyroid. 2023. PMID: 37855745
Organizational Impact of Immunotherapies in Advanced Cancers in France.
Grumberg V, Chouaïd C, Gaudin AF, Le Tourneau C, Marabelle A, Bongiovanni-Delarozière I, Cotté FE, Borget I. Grumberg V, et al. Among authors: borget i. JCO Glob Oncol. 2023 Aug;9:e2300026. doi: 10.1200/GO.23.00026. JCO Glob Oncol. 2023. PMID: 37595168 Free PMC article. Review.
194 results